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Abstract
Resumo
Objective: To assess changes in the great saphenous vein (GSV) after foam sclerotherapy for varicose veins.
Materials and Methods: This was a prospective study of 33 patients who were treated with polidocanol foam sclerotherapy after 
having had varicose veins with a clinical severity-etiology-anatomy-pathophysiology classification of C4–C6 for three months. The 
patients were evaluated by ultrasound before, during, and after the procedure (on post-procedure days 7, 15, 30, 60, and 90). The 
GSV diameter, the rate of venous occlusion, and the rate of reflux elimination were determined. Two patients were excluded for 
having a history of deep vein thrombosis history, and one was excluded for having bronchial asthma.
Results: Thirty patients (26 females and 4 males, with mean age of 62 years) completed the protocol. The mean pre-procedure GSV 
diameter was 6.0 ± 0.32 mm (range, 3.6–11.2 mm). During the sclerotherapy, the mean GSV diameter was reduced to 1.9 ± 0.15 
mm (range, 0.6–3.8 mm). On post-procedure day 7, the mean GSV diameter increased to 6.3 ± 0.28 mm (range, 3.9–9.7 mm). On 
post-procedure day 90, the mean GSV diameter was 4.0 ± 0.22 mm (range, 1.9–8.2 mm). The rate of GSV reflux was significantly 
lower in the assessment performed on post-procedure day 90 than in the pre-procedure assessment (p < 0.0028).
Conclusion: On the basis of our ultrasound analysis, we can conclude that foam sclerotherapy for varicose veins results in a signifi-
cant reduction in GSV diameter, as well as in the elimination of GSV reflux.
Keywords: Ultrasonography; Varicose veins; Sclerotherapy; Saphenous vein; Venous insufficiency.
Objetivo: Avaliar alterações ultrassonográficas na veia safena magna (VSM) após escleroterapia com espuma para varizes.
Materiais e Métodos: Estudo prospectivo de 33 pacientes com varizes classificadas como C4–C6 (classificação clinical severity- 
etiology-anatomy-pathophysiology), durante três meses, submetidos a escleroterapia com espuma de polidocanol. Os pacientes 
foram acompanhados por ultrassonografia vascular antes, durante e 7, 15, 30, 60 e 90 dias após o procedimento. Avaliaram-se o 
diâmetro da VSM, a taxa de oclusão venosa e a taxa de abolição do refluxo. Dois indivíduos foram excluídos do estudo por apresen-
tarem história prévia de trombose venosa profunda e um paciente não participou do estudo por asma brônquica.
Resultados: Dos 30 pacientes que completaram o protocolo, 26 eram do sexo feminino e 4 eram do sexo masculino, com idade média 
de 62 anos. O diâmetro da VSM médio pré-operatório foi 6,0 ± 0,32 mm (variação: 3,6–11,2 mm). Na escleroterapia, houve redução 
do diâmetro médio para 1,9 ± 0,15 mm (variação: 0,6–3,8 mm). Em 7 dias, houve aumento médio do diâmetro da VSM para 6,3 ± 
0,28 mm (variação: 3,9–9,7 mm). Em 90 dias, o diâmetro da VSM médio reduziu para 4,0 ± 0,22 mm (variação: 1,9–8,2 mm). O 
refluxo venoso apresentou redução estatisticamente significante entre o pré-operatório e pós-operatório após 90 dias (p < 0,0028).
Conclusão: Com base em nossa análise ultrassonográfica, podemos concluir que a escleroterapia com espuma para varizes resulta 
em uma redução significativa do diâmetro da VSM, bem como abolição do refluxo da VSM.
Unitermos: Ultrassonografia; Escleroterapia; Varizes; Veia safena; Insuficiência venosa.
as being affordable, providing esthetic improvement, and 
requiring patients to take little time off from work(1).
The advent of Doppler vascular ultrasound has driven 
new endovascular treatment methods, such as laser photo-
coagulation, radiofrequency ablation, and foam sclerother-
apy, the last having proven to be an attractive technique, 
INTRODUCTION
The ideal treatment for primary varicose veins in the 
lower extremities should be minimally invasive, repeated 
when necessary, and free from significant complications. It 
should also be effective for eliminating points of reflux and 
reducing venous hypertension at the extremities, as well 
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because anesthesia, hospital admission, and post-treat-
ment bed rest are unnecessary(2). The foam is produced by 
mixing a sclerosing agent with room air and can be used to 
treat saphenous veins as well as trunk varicose veins and 
perforating veins, particularly in advanced cases with skin 
lesions and ulcers(3,4). Doppler vascular ultrasound is in-
dispensable for performing the procedure and for follow 
up, because it can monitor occlusion of the vein and detect 
reflux relapses(5).
The objective of this study was to use duplex ultra-
sound to evaluate changes in the diameter of the great sa-
phenous vein (GSV) and the rate of venous reflux elimina-
tion after treatment with polidocanol foam sclerotherapy.
MATERIALS AND METHODS
This was an open prospective study evaluating the 
impact that polidocanol foam sclerotherapy for chronic 
venous insufficiency (CVI) has on the diameters of the 
saphenous veins treated and on the rate of venous oc-
clusion. The study was conducted at a private vascular 
surgery clinic between February and September of 2009. 
The study was approved by the institutional ethics com-
mittee, and all participating patients gave written in-
formed consent.
The inclusion criteria were being ≥ 18 years of age; 
having lower-limb CVI classified as clinical stage C4, C5, 
or C6 according to the clinical severity-etiology-anatomy-
pathophysiology (CEAP) classification(6); and proximal, 
multisegmental, or diffuse reflux in the GSV(7). Patients 
in whom ultrasound showed acute deep vein thrombosis 
or deep vein thrombosis that was not recanalized were ex-
cluded, as were those with varicose veins unrelated to GSV 
reflux and those who had previously undergone varicose 
vein surgery, as well as those with thrombophilia, active 
neoplasm or cancer under surveillance, lung disease, or pe-
ripheral arterial disease (ankle-brachial index < 0.9).
Sclerotherapy technique
The sclerotherapy technique employed in the present 
study has been described elsewhere(8). The patients under-
went treatment of the GSV and of tributary varicose veins. 
When complete closure of target veins was not achieved, 
additional sessions were conducted until complete closure 
was achieved. Additional sessions, with one or more punc-
tures, were conducted, as necessary (on a case-by-case ba-
sis), at 7-day intervals. In all cases, foam was produced by 
mixing 3% polidocanol with room air, at a proportion of 
1:4, and the total volume of foam per session did not ex-
ceed 10 mL(9).
After the injection of the foam, the limb was elevated 
and bound with 12-cm wide inelastic bandages, which 
were left in place for three days, and patients wore 30/40 
mmHg 7/8 elastic compression stockings for three months 
thereafter. At the end of the procedure, patients were in-
structed to walk and to resume their normal routines.
Ultrasound assessment
The examinations were standardized and were all con-
ducted by the same physician. Patients were examined in 
a standing position with their weight on the contralateral 
leg, with the limb being examined in external rotation and 
the calf musculature relaxed, maintaining stability. We 
employed an ultrasound system (EnVisor; Philips Medical 
Systems, Andover, MA, USA) with a 10–12 MHz multi-
frequency transducer. The deep vein system was assessed 
for acute or previous venous thrombosis. The examination 
of the superficial vein system focused on the sapheno-
femoral and saphenopopliteal junctions, together with the 
great and small saphenous veins, as well as on identify-
ing incompetent perforating veins. Reflux was induced 
by manual compression of the calf and defined as flow in 
the retrograde direction for periods greater than 0.5 s for 
saphenous veins and 0.35 s for perforating veins(10). The 
GSV diameter was measured at three points: at the sa-
phenofemoral junction; in the proximal third of the thigh, 
5 cm distal to the inguinal crease; in the middle third of 
the thigh, between the inguinal crease and the knee joint 
line; and in the distal third of the thigh, 5 cm proximal to 
the knee joint line. The mean of these measurements was 
calculated for the purposes of comparison.
In most cases, patients underwent seven ultrasound 
assessments: the first assessment—performed prior to the 
procedure, to identify reflux patterns; the second assess-
ment—performed during the procedure, with the objective 
of guiding puncture of the GSV, monitoring injection of 
the foam and preventing it from entering the deep vein sys-
tem; the third assessment—performed on post-procedure 
day 7, with the objective of detecting deep vein thromboses 
and verifying the occlusion of the GSV; the fourth, fifth, 
and sixth assessments—performed on post-procedure days 
15, 30, and 60, respectively, to evaluate venous thrombus 
and changes in the diameter of the GSV; and the seventh 
assessment—performed on post-procedure day 90, to as-
sess treatment efficacy. Patients in whom the GSV was not 
occluded by the time of the third assessment underwent 
another foam sclerotherapy session and an assessment 
following the criteria and objectives of the second assess-
ment, therefore undergoing a total of eight ultrasound as-
sessments.
Statistical analysis
The Bartlett test was applied in order to assess the ho-
mogeneity of variances, and the Shapiro-Wilk test was em-
ployed to determine whether the study data fitted a normal 
distribution. Fisher’s exact test was used in order to deter-
mine whether there was an association between treatment 
failure and occlusion of the GSV. Statistical calculations 
were made on an electronic spreadsheet (Microsoft Excel 
2000), and statistical analyses were performed with the 
IBM SPSS Statistics software package, version 23.0 (IBM 
Corporation, Armonk, NY, USA).
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RESULTS
We recruited 33 patients with primary varicose veins 
in the lower extremities. In all of the patients, the primary 
varicose veins were classified as CEAP clinical stage C4, 
C5, or C6 and GSV reflux was classified as proximal, multi-
segmental, or diffuse. Of those 33 patients, 3 were excluded: 
two for having a history of deep vein thrombosis, and 1 
for having bronchial asthma. Therefore, a total of 30 pa-
tients—26 women and 4 men, with a mean age of 62 years 
(range, 32–70 years)—completed the 90-day protocol. 
The primary varicose vein was classified as CEAP C4 
in 19 patients (63.3%), as CEAP C5 (with healed ulcers) 
in 5 (16.7%), and as CEAP C6 (with unhealed ulcers) in 6 
(20.0%). All of the patients showed GSV reflux, which was 
classified as diffuse in 12 patients (40%) and as proximal in 
9 (30%). In the pre-procedure assessments, the mean GSV 
diameter was 6.0 ± 3.2 mm (range, 3.6–11.2 mm).
The first change to the saphenous vein observed on 
duplex ultrasound immediately after injection of the foam 
is a rapid reduction in the caliber of the vessel, caused by 
the vasospasm provoked by the foam. Figure 1 illustrates 
the reduction in caliber of the saphenous vein in one of the 
patients evaluated in the present study. During sclerother-
apy, the mean GSV diameter was 1.9 ± 0.15 mm (range, 
0.6–3.8 mm). In the follow-up ultrasound examination 
performed on post-procedure day 7, the calibers of treated 
GSVs had increased, the mean diameter being 6.3 ± 0.28 
mm (range, 3.9–9.7 mm). All veins that had been treated 
with sclerotherapy were not compressible with the trans-
ducer, exhibiting parietal thickening, as well as luminal 
content with a homogenous appearance that was predomi-
nantly hypoechoic. In all cases, there was no flow seen on 
color or pulsed-wave Doppler.
To achieve total occlusion of the GSV, 26 patients 
(86.6%) required only a single session of sclerotherapy, 3 
(10%) required two sessions, and 1 (3.3%) required three 
sessions. During the subsequent examinations, gradual 
contraction of the luminal content was observed and, con-
sequently, there was a reduction in the mean diameter of 
the saphenous veins treated. The mean GSV diameter was 
5.7 mm (range, 3.3–9.8 mm) on post-procedure day 15, 
5.0 mm (range, 3.1–9.2 mm) on post-procedure day 30, 
4.4 mm (range, 2.3–8.8 mm) on post-procedure day 60, 
and 4.0 mm (range, 1.9–8.2 mm) on post-procedure day 
90. There was a statistically significant difference between 
the mean GSV diameter on post-procedure day 90 and that 
recorded at baseline (p < 0.001). Figure 2 illustrates the 
GSV diameter on post-procedure days 7 and 90.
Figure 3 illustrates the evolution of the mean GSV 
diameter over time. Before treatment, the mean diameter 
Figure 1. Ultrasound images of 
the GSV. A: Caliber of the vein 
before treatment (d = 7.8 mm). 
B: Reduction in caliber in re-
sponse to injection of the foam 
(d = 4.3 mm).A B
Figure 2. Ultrasound images 
of the GSV after the procedure. 
A: Caliber of the vein at 7 days 
after the procedure (d = 8.2 
mm). B: Caliber of the vein at 
90 days after the procedure (d 
= 5.1 mm).A B
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was 6.0 mm, decreasing to 1.9 mm immediately after injec-
tion of the foam. By post-procedure day 7 days, the mean 
GSV diameter had increased to 6.3 mm and underwent a 
gradual reduction over the course of the subsequent as-
sessments, reaching 4.0 mm at 90 days after the treatment.
Duplex ultrasound analysis revealed a statistically sig-
nificant reduction in the proportion of patients showing 
GSV reflux, from the pre-procedure rate of 100% to a 90-
day post-procedure rate of 13.3% (p = 0.0028). In terms of 
the elimination of reflux, 22 (73%) of the saphenous veins 
treated were found to be totally occluded on post-procedure 
day 90. At that same time point, we identified eight recana-
lizations, of which seven were partial (three with reflux and 
four without) and just one was complete (with reflux).
With regard to complications, eight (27%) of the pa-
tients experienced episodes of scintillating scotoma after 
injection of the foam, without any other systemic compli-
cations. No major events, such as deep venous thrombosis 
or pulmonary embolism, were observed.
DISCUSSION
Successful sclerotherapy for the treatment of lower-
extremity varicose veins requires detailed planning. In 
general, sclerotherapy is conducted respecting the order 
of the reflux points, working from larger caliber varicose 
veins to those with smaller caliber(11). Therefore, adequate 
clinical and anatomic assessments must be performed be-
fore treatment(12).
In addition to the clinical assessment, vascular ul-
trasound plays a crucial role in the assessment of venous 
reflux in the lower extremities. It is a low-cost, noninva-
sive examination that is well tolerated by patients. It of-
fers direct visualization, localization, and quantification of 
venous reflux with 95% sensitivity and 100% specificity(10).
This study assessed the impact that CVI treatment 
with foam sclerotherapy had on the GSV diameter and 
the rate of venous occlusion. The majority of the patients 
in the sample were classified as being in the more ad-
vanced stages of the disease, and all the patients showed 
GSV reflux.
The fact that there were no major complications, such 
as deep venous thrombosis or pulmonary embolism, in our 
sample is in line with other findings in the medical lit-
erature(13). The pigmentation rate in our sample was 13%, 
phlebitis requiring drainage occurring in two cases (6%). 
In one case, we observed partial propagation of the throm-
bus from the GSV into the deep vein system, although it 
affected less than 50% of the femoral vein lumen, with 
spontaneous regression and no need for treatment. In 
keeping with the results of one systematic review(13), we 
observed post-procedure phlebitis in 16 patients (53%), 
although drainage of clots was necessary in only two of 
those patients.
Reduction in the caliber of treated veins is a common 
finding in post-procedure ultrasound examinations(14). In 
our patient sample, we observed a statistically significant 
(33%) reduction in GSV diameters at 90 days after sclero-
therapy.
Rasmussen et al.(15) compared four techniques avail-
able for treatment of saphenous vein reflux (intravenous la-
ser ablation, radiofrequency ablation, foam sclerotherapy, 
and conventional surgery) and observed that the recana-
lization rate after foam sclerotherapy was approximately 
20%, without repercussions for symptoms, as reflected in 
the results on quality-of-life questionnaires. In the present 
study, the rate of reflux elimination at 90 days was 87%, 
which is comparable to rates described in the literature(13). 
Analysis of the rates of saphenous vein occlusion shows 
that the results of foam sclerotherapy are systematically 
inferior to those of thermal ablation techniques and con-
ventional surgery(14–16). Nevertheless, the lower rates of 
occlusion and higher rates of recanalization/reflux relapse 
in veins treated with foam do not result in worse patient 
quality-of-life scores(14–17). One possible explanation for 
the maintenance of quality-of-life scores, even after re-
canalization with reflux in treated saphenous veins, is the 
considerable reduction in vein diameter and the closure of 
tributaries that drain reflux.
Although our study has some limitations, including 
the small sample size and relatively short follow-up period, 
it has demonstrated that foam sclerotherapy effectively 
eliminated axial reflux in saphenous veins and resulted in a 
significant reduction in venous diameters. Further studies 
are needed in order to determine whether the reduction of 
venous diameter truly contributes to the maintenance of 
the good quality-of-life scores obtained with foam sclero-
therapy for CVI.
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